Medicine details
Image | |
Name | Ezetrol |
Dosage | Tablet |
Generic Name | Ezetimibe |
Classes |
Metabolic Agent Antihyperlipidemic/Lipid Lowering Agent |
Diseases |
High Cholesterol Metabolic Disorder |
Company | Unimed & Unihealth Manufacturers Ltd. |
Drug Package Details
Strength | 10 mg |
Storage Condition | |
Origin Country | Bangladesh |
Commercial Pack | 30 |
Price per pack | ৳ 300.00 |
Cost per pack | ৳ 264.00 |
Package unit | 10 tabs strip |
Price per unit | ৳ 10.00 |
Cost per unit | ৳ 8.80 |
Discount | 0 |
Coupon | |
Remarks |
Ezetimibe
Ezetimibe is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols. Ezetimibe reduces total-C, LDL-C, Apo B, and TG, and increases HDL-C in patients with hypercholesterolemia.
Ezetimibe is indicated for Primary Hypercholesterolemia and Hyperlipidemia (adjunct therapy with a statin).
- The patient should be placed on a standard cholesterol-lowering diet before receiving Ezetimibe and should continue on this diet during treatment with Ezetimibe.
- The recommended dose of Ezetimibe is 10 mg once daily. Ezetimibe can be administered with or without food.
- Ezetimibe may be administered with an HMG-CoA reductase inhibitor (in patients with primary hypercholesterolemia) or with fenofibrate (in patients with mixed hyperlipidemia) for incremental effect.
- For convenience, the daily dose of Ezetimibe may be taken at the same time as the HMG-CoA reductase inhibitor or fenofibrate, according to the dosing recommendations for the respective medications.
Side effects commonly associated with ezetimibe include-
- Asthenia
- Diarrhea
- Cough
- Back pain
- Nasopharyngitis
- Concurrent administration of Ezetimibe with a specific HMG-CoA reductase inhibitor or fenofibrate should be in accordance with the product labeling for that medication.
- In post-marketing experience with Ezetimibe, cases of myopathy and rhabdomyolysis have been reported regardless of causality. Most patients who developed rhabdomyolysis were taking an HMG-CoA reductase inhibitor prior to initiating Ezetimibe.
- Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, Ezetimibe is not recommended in these patients.
- When ezetimibe is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and product labeling for the HMG-CoA reductase inhibitor.
Contraindication
Hypersensitivity to any component of this medication.
The combination of ezetimibe with an HMG-CoA reductase inhibitor is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.